Obesity Clinical Trials in New York

Showing 61-80 of 221 trials

A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

NCT06313528

The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.

Obesity

Eli Lilly and Company85 participantsStarted Mar 2024

Orlando, Florida, United States • Baton Rouge, Louisiana, United States • New York, New York, United States

Active Not RecruitingPhase 3< 1 mile

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

NCT05882045

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

ObesityCardiovascular Diseases

Eli Lilly and Company1,800 participantsStarted May 2023

Phoenix, Arizona, United States • Covina, California, United States • Fresno, California, United States +166 more locations

A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Obesity Trials in Other Cities

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program

Spatz3 Adjustable Balloon System® (Spatz3) Post Approval Study

The Retrain Your Brain for Healthy Eating Study

TREAT to Improve Cardiometabolic Health

Reducing Obesity Using Social Ties Program

Low GI Diet in Children and Adolescents With ALL

Chronic Widespread Pain After Rapid Weight Loss in Non-Hispanic Black and Hispanic/Latino/a/x Adults

Health e-Baby: Trial to Reduce Obesity Risk Factors During the First 1,000 Days

Multi-level Supermarket Discount Study

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

Cardiovascular Risk Screening and Risk Reduction in Women Vets

Long Term Extension Trial of Setmelanotide

Pediatric Obesity Weight Evaluation Registry (POWER) Study

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Other Conditions in New York